Bausch Health Companies
BHC | NYSE
$8.42
+$0.07 (+0.90%)
At close: Nov 16, 2026, 4:00 PM ET
$8.43
+$0.01 (+0.09%)
After-hours:
Nov 16, 2026, 5:15 PM ET
Bausch Health Companies Company Profile
Company profile explainedCompany Profile
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Key Executives
| Name | Position |
|---|---|
| Thomas J. Appio | Chief Executive Officer & Director |
| Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer |
| Mirza Dautbegovic | Executive Vice President & Chief Operating Officer |
| Aimee J. Lenar | President of US Pharma |
| Cees Heiman | Senior Vice President of Europe & Canada |
| Garen Sarafian | Vice President & Head of Investor Relations |
| Jiny Kim | Senior Vice President of Solta Medical |
| Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer |
| Seana Carson | Executive Vice President & General Counsel |
| Steven Lee | Senior Vice President, Controller & Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 29, 2026 | 10-Q | Quarterly Report |
| Oct 28, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Aug 20, 2026 | 4 | Filing |
| Jul 30, 2026 | 10-Q | Quarterly Report |
| Jul 29, 2026 | 8-K | Current Report |
| Jul 20, 2026 | 4 | Filing |
| Jul 17, 2026 | 4 | Filing |
Bausch Health Companies
| Country | Canada |
| IPO Date | Mar 29, 1994 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 20,300 |
| CEO | Thomas J. Appio |
Contact Details
2150 St. ElzEar Boulevard West Laval,
QC H7L 4A8 Canada
Stock Details
| Ticker Symbol | BHC |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000885590 |
| CUSIP Number | 071734107 |
| ISIN Number | CA0717341071 |
| SIC Code | 2834 |
Recent News
- 4 days ago / zacks.comHere's Why Bausch Health (BHC) is a Strong Momentum Stock
- 11 days ago / prnewswire.comBausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026
- 13 days ago / zacks.comBHC Q3 Earnings Call Highlights Raised Outlook, Xifaxan Risks
- 14 days ago / zacks.comIs Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
- 19 days ago / zacks.comBHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
- 19 days ago / seekingalpha.comBausch Health Companies Inc. (BHC) Q3 2026 Earnings Call Transcript
- 19 days ago / zacks.comBausch (BHC) Reports Q3 Earnings: What Key Metrics Have to Say
- 19 days ago / zacks.comBausch Health (BHC) Surpasses Q3 Earnings and Revenue Estimates
- 19 days ago / marketbeat.comWhat Bausch Health Cos (BHC) Said on Its Q3 Earnings Call
- 19 days ago / prnewswire.comBausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Add to Watchlist
Select watchlists to add or remove BHC